Docetaxel Combined with Celecoxib in Neoadjuvant Breast Cancer Therapy

COX-2 Expression as Prognostic Biomarker

• February 15, 2019
• Reading time: 1 minute

On January 31, 2019, the Journal of Clinical Oncology published exploratory analysis from the REMAGUS02 Phase III trial examining the relationship between COX-2 inhibition via celecoxib and COX-2 gene expression (PTGS2) in locally advanced HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.

Trial Design

Among 156 locally advanced, COX-2-expressing HER2-negative breast cancer patients:

Group 1: Epirubicin plus cyclophosphamide (standard regimen) followed by Docetaxel plus Celecoxib

Group 2: Epirubicin plus cyclophosphamide followed by Docetaxel monotherapy

Stratification: age, menopausal status, TNM classification, hormone receptor status

Key Findings

COX-2 Low-Expression Subgroup:

• Concurrent docetaxel plus celecoxib resulted in reduced event-free survival and overall survival

COX-2 High-Expression Subgroup:

• No significant impact of celecoxib addition

Clinical Significance

Results demonstrate that COX-2 expression status serves as a predictive biomarker for celecoxib efficacy in breast cancer neoadjuvant therapy. Patient stratification by COX-2 expression may optimize therapeutic outcomes and minimize unnecessary toxicity.

Data Source

Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. Journal of Clinical Oncology, Published online January 31, 2019.

Clinical Note: Treatment decisions require consultation with oncology specialists regarding individual biomarker status and therapeutic optimization.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1